Blueprint medicine stock drivers#

Today we are delivering our approved medicines directly to patients in the United States and Europe and we are advancing multiple programs for systemic mastocytosis lung cancer and other genomically defined cancers and cancer immunotherapy. Since 2011 we have leveraged our research platform including expertise in molecular targeting and world-class drug design capabilities to rapidly and reproducibly translate science into a broad pipeline of precision therapies.

Blueprint medicine stock drivers#

Applying an approach that is both precise and agile we create medicines that selectively target genetic drivers with the goal of staying one step ahead across stages of disease. The firm was recently trading at a 52-week low of $37.82 on Februand set a 52-week high on Septemat $79.4.īlueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and blood disorders. Before the report, Blueprint Medicines Corp received a Long-Term Technical Rank by InvestorsObserver of 72, putting it in the top half of stocks. InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.īlueprint Medicines Corp has performed a little above average during the past few months.

Wall Street Analysts had an average rating of Buy on the stock prior to the report. The stock is up 14.03% to $59.16 after the report.īlueprint Medicines Corp's earnings expanded faster than revenues, signaling widening profit margins.

In the same quarter a year ago, the company lost $1.79 per share on revenue of $62.7 million. On the revenue line, the company reported $63.3 million, beating estimates by $21.3 million. Blueprint Medicines Corp ( BPMC) said before open Thursday that it lost $2.15 per share in quarter one 2023.